What is the incidence of hypomagnesemia among patients treated with cetuximab?

Updated: Oct 30, 2020
  • Author: Tibor Fulop, MD, PhD, FACP, FASN; Chief Editor: Vecihi Batuman, MD, FASN  more...
  • Print
Answer

Interestingly, mutations of the epithelial growth factor (EGF) have been associated with reduced expression of TRPM6 [25]  and thus, with hypomagnesemia; cancer medications that are EGF receptor inhibitors (eg, cetuximab, panitumumab) can also cause hypomagnesemia. [26, 27, 28, 29]  In a meta-analysis of 10 randomized controlled trials involving a total of 7,045 patients with advanced cancers, the overall incidence of grade 3/4 hypomagnesemia among patients treated with cetuximab was 3.9% (95% confidence interval [CI], 2.6–4.3). Compared with patients who received control medication, those who received cetuximab had a significantly increased risk of grade 3/4 hypomagnesemia (relative risk, 8.60; 95% CI, 5.08–14.54). The increased risk varied with tumor type, with the highest incidence in non–small cell lung cancer and the lowest incidence in colorectal cancer. [30]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!